Hepatic fat changes with antisense oligonucleotide therapy targeting ANGPTL3

Andre Zimerman, Stephen D. Wiviott,Jeong-Gun Park,Sabina A. Murphy,Xinhui Ran,Candace R. Bramson,Madelyn Curto,Vesper Ramos, Alexandra Jevne,Julia F. Kuder,Subodh Verma,Wojtek Wojakowski,Steven G. Terra,Marc S. Sabatine,Brian A. Bergmark, Nicholas A. Marston

Journal of clinical lipidology（2023）

引用 0|浏览3

暂无评分

摘要

•Vupanorsen, an ASO targeting ANGPTL3, reduced TGs but increased hepatic fat.•227 patients randomized to vupanorsen or placebo were included in this analysis.•Increases in hepatic fat related to ANGPTL3 inhibition and baseline risk factors.•Hepatic fat changes with vupanorsen only moderately correlated with AST and ALT.•Hepatic fat should be monitored in trials of triglyceride-lowering therapies.

查看译文

关键词

ANGPTL3,Hepatic fat,Triglycerides,Antisense oligonucleotide,Randomized trial

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要